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Abstract
Aims To investigate the still uncertain independent prognostic impact of pulse pressure (PP) in acute heart failure (HF), in
particular across the left ventricular ejection fraction (EF) phenotypes, and the potential contribution of PP in outlining the in-
dividual phenotypes.
Methods and results We prospectively evaluated 1-year death and rehospitalization in 4314 patients admitted for acute
HF grouped by EF and stratified by their PP level on admission. In HF with reduced (< 40%) EF (HFrEF), the highest quar-
tiles of PP had the lowest unadjusted [hazard ratio (HR) 0.77, 95% confidence interval (CI) 0.61–0.98] and adjusted (HR 0.64
0.50–0.82) risk of 1 year all cause death compared to the lowest quartile. Its prognostic impact was partially mediated by
systolic blood pressure (SBP). In HF with preserved (≥ 50%) EF (HFpEF), the intermediate quartile of PP showed the lowest
1 year all cause mortality in unadjusted (HR 0.598, CI 0.416–0.858) and adjusted (HR 0.55, 95% CI 0.388-0.801) models with
no relationship with SBP. In a receiver operating characteristic analysis, a combination of PP > 60 mmHg and
SBP > 140 mmHg was associated to a preserved EF with a high performance value. No prognostic significance of PP
was found in the HF with mid-range EF subgroup.
Conclusions In acute HFrEF, there is an almost linear inverse relation between mortality and PP, partly mediated by SBP. In
HFpEF, a J-shaped relationship between mortality and PP was present with a better prognosis at the nadir. A combination of
PP > 60 mmHg with SBP > 140 mmHg may be clinically helpful as marker of a preserved left ventricular EF.
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Introduction
Pulse pressure (PP) is the difference between systolic and di-
astolic blood pressure (BP) and reflects the complex interac-
tion between left ventricular (LV) function and the elastic
properties of the proximal large vasculature.1 Particularly,
when the central arteries become stiffer, in aging as in heart
failure (HF), the reflected wave arising from the peripheral ar-
terial vessels travels faster and moves from diastole to systole
increasing SBP (SBP), decreasing diastolic BP and widening
PP.2 The widening of PP imposes a greater burden on the
LV affecting both systolic and diastolic function, favouring
LV hypertrophy and impairing coronary blood flow.1
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Increased PP is associated with an increased risk of myocar-
dial infarction and cardiovascular (CV) mortality in normoten-
sive, hypertensive, and high-risk patients3,4 and with
increased risk of HF in the elderly.5 Higher PP favours the de-
velopment of coronary artery disease4 and is an independent
prognosticator of re-infarction and all-cause mortality after
myocardial infarction (MI) in patients with LV systolic dys-
function.6 Because a stiffening of the large elastic arteries de-
termines a similar impairment in functional capacity in HF
with reduced ejection fraction (EF) < 40% (HFrEF) and HF
with preserved EF ≥ 50% (HFpEF) LVEF,7,8 also a similar be-
haviour of PP could be expected in both EF phenotypes. How-
ever, data regarding the prognostic significance of PP in
patients with acute HFrEF and HFpEF are unclear.9,10 Low
PP has emerged as an independent predictor of mortality in
patients with acute HFrEF,11,12 and in these patients it is be-
lieved to reflect mainly an excessive reduction in stroke vol-
ume rather being an index of arterial stiffening. In patients
with acute HFpEF, and even more in those with HF mid-range
EF (HRmEF), the prognostic role of PP is far less
established,13,14 and inconsistent results were reported,9,13,14
Apart its prognostic role, we also speculated the possible
clinical utility of PP amplitude to discriminate the two HF phe-
notypes because in the acute setting they both present with
similar clinical symptoms and signs.15 To address these clinical
issues, we prospectively investigated a large multinational Eu-
ropean cohort of acute HF (AHF) patients followed up for




The principles and procedures of the European Society of Car-
diology (ESC)-Heart Failure Association EURObservational Re-
search Programme (EORP) HF Long-Term Registry, a study of
the EORP of the ESC and the ESC-Heart Failure Association
have been previously described.16 The enrolling network of
this prospective, multicentre, and observational study in-
cluded 211 Cardiology centres of 21 European and Mediterra-
nean ESC member countries. National network coordinators
were identified by the participating National Societies of Car-
diology, and several training meetings were organized for the
study investigators to assure consistency in definition and
data collection. A diagnosis of AHF (both de novo and wors-
ening HF) was made by the clinician–investigators at initial
presentation and required the presence of signs and symp-
toms of HF, evidence of cardiac dysfunction, and the need
for intravenous therapy. From May 2011 to April 2013, all pa-
tients admitted for acute HF during the enrolment period (on
1 day per week for 12 consecutive months) were included in
this registryThe registry management, the central data quality
control, and the statistical analysis were performed by the
EORP Department of the ESC. For a random sample of 5%
of centres, data source verification was performed by EORP
monitors. There were no specific exclusion criteria, except
for age ≤ 18 years. Data were collected using a web-based
system. The registry was approved by each local Institutional
Review Board according to the rules of each participating
country. All patients gave written informed consent before
discharge.
Clinical and laboratory data
Blood pressure was measured on hospital admission, and PP
was calculated as the difference between systolic and dia-
stolic BP. Patients were considered as having hypertension
if their BP was ≥ 140/90 mmHg or if they were taking antihy-
pertensive drugs. Biochemical blood measurements were de-
termined using local standard laboratory procedures.
According to the pure observational nature of the study,
the large involvement of many heterogeneous European
countries and the urgency clinical status of patients enrolled
the BP measurement technique was not predetermined by
protocol. Conventional trans-thoracic echocardiography was
used to measure EF according to international standard
criteria. Patients were stratified according to LVEF as HF with
preserved ≥ 50% (HFpEF), reduced < 40% (HFrEF), and mid-
range 40–49% EF (HFmEF).17
Statistical analyses
In the current analysis, we present the 1 year data from the
ESC-EORP HF Long-Term registry concerning the rates of the
cumulative (in-hospital and post-discharge) all cause of death,
the post-discharge 1 year all cause mortality and 1 year CV-
death, 1 year all cause re-hospitalization, and 1 year CV-
rehospitalization in acute HFrEF, HFmEF, and HFpEF stratified
by PP on admission. Descriptive statistics were used to sum-
marize frequency tabulations (%) and distributions
(mean ± standard deviation). A Cox proportional hazards
model was used to assess the association between PP quar-
tiles and outcomes. In addition to unadjusted hazard ratios
(HRs), adjusted HRs were estimated after adjustment for
pre-specified potential confounding factors selected on the
basis of their clinical or biological plausibility, namely age,
gender, HF aetiology (ischemic vs. non-ischemic), renal dys-
function, and diabetes. The role of SBP on the prognostic im-
pact of PP was also explored by dividing the population in
three groups of SBP (< 100mmHg, between 100–139mmHg,
and > 140 mmHg) accordingly to the results of several stud-
ies.18–20 All conclusions were drawn separately by individual
HF phenotype. A test for trend was also planned, but no
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evidence of linear trend was found in the main analysis using
the quartile of PP in categories. A ROC analysis to evaluate
the ability of PP to discriminate a preserved or a reduced EF
in AHF was also performed. A two-sided P value of < 0.05
was considered as statistically significant. All analyses were
performed using SAS Statistical software version 9.4 (SAS Insti-
tute, Inc., Cary, NC, USA).
Results
Baseline characteristics of heart failure with
reduced ejection fraction, heart failure with
mid-range ejection fraction, heart failure with
preserved ejection fraction groups and pulse
pressure quartiles
Among the patients enrolled in the registry, 6629 were hospi-
talized with a primary diagnosis of AHF. Out of them, 6618
had PP available, but only 4314 had also the EF available;
217 died in-hospital (5%). Median follow-up time was 378
(288–415) days, during which 271 (6%) patients discharged
alive were lost to follow-up, then 4097 patients were in-
cluded in the present analysis.
According to a brachial SBP classification, 26.8% of patients
presented within the range ≤ 80–110 mmHg (< 2% with
values < 85 mmHg), 42.9% with 110–140 mmHg, and
30.3% with >140 mmHg, respectively. Then, on admission,
> 70% of patients had a brachial SBP > 110 mmHg. The sub-
jects distributed according to the EF-phenotypes were 2213
(51.3%) HFrEF, 818 (19.0%) HFmEF, and 1283 (29.7%) HFpEF.
Main baseline characteristics of the EF-subtypes are reported
in Table 1. Age was increasing along with the increase in EF
among the considered three EF subgroups (from 65.8 [12.8]
to 71.9 [13.1] years), whereas the male gender prevalence
was decreasing (from 76.4% to 45.1%), and the prevalence
of the New York Heart Association (NYHA) functional class
III–IV was similar (88–83%). Ischemic aetiology was prevalent
in HFrEF (62.6%) and HRmEF (65.4%) and not in HFpEF
(37.6%). Hypertension was highly represented in all three
groups, particularly in HFpEF (76.1%), in which the atrial fibril-
lation (AF) rate was also high (55%) whereas the prevalence
was 38% and 44% in HFrEF and HFmEF, respectively.
Angiotensin-converting enzyme inhibitors, angiotensin II re-
ceptor blockers, aldosterone antagonists, beta-blockers,
antiplatelets drugs, and lipid-lowering drugs were prevalent
in HFrEF and HRmEF. Oral anticoagulants were more utilized
in HFpEF (39.9%). The crude 1 year all-cause death, CV death,
cumulative all-cause deaths, all cause re-hospitalization, CV
rehospitalisation and in-hospital death in the three groups
are reported in Table 2. All end-point events (except the in-
hospital mortality, P 0.78) were significantly higher
(P < 0.001) in patients with HFrEF.
The baseline characteristics of the PP quartiles in HFrEF,
HRmEF and HFpEF are reported in Supporting Information
Table S1. The patients of the highest PP quartile as compared
to the patients of the lower PP quartiles were significantly
and uniformly older, with higher proportion of female, higher
BMI, and higher proportion of diabetes, hypertension, and is-
chemic heart disease. As expected, these patients were more
likely to be treated with antihypertensive drugs as
angiotensin-converting enzyme inhibitors, angiotensin II re-
ceptor blockers, and calcium channel blockers. In contrast,
patients in the lowest PP quartile were shown to have lower
systolic and diastolic BP, lower sodium plasma concentration,
higher rate of AF and were more frequently treated with an-
ticoagulant drugs, beta-blockers, aldosterone antagonists,
digitalis, and diuretics as compared to the highest quartile. In-
terestingly, patients in NYHA III–IV functional class were sig-
nificantly more represented in the lowest PP quartile in the
HFrEF group, whilst no difference in NYHA functional class
was observed across PP quartiles in HRmEF and HFpEF.
Prognostic impact of pulse pressure in ejection
fraction subgroups
Cox proportional hazard models of PP quartiles or continuous
PP value at hospital admission with the individual endpoints
in acute HFrEF, HFmEF, and HFpEF are shown in Table 3. In
HFrEF, patients in the intermediate and highest quartile com-
pared to patients in the lowest quartile had a 33.9% and
22.6% significantly lower unadjusted relative risk of death, re-
spectively. This association was strengthened after adjusting
for age, gender, HF aetiology, diabetes, and renal dysfunction
with a 39.5% and 35.9% significant reduction in relative risk of
death, respectively. All the other endpoints showed similar
lower event rates either in unadjusted or in adjusted models
for intermediate and higher PP quartiles. This was confirmed
also when PP was considered as a continuous variable. In
both the analyses of crude 1 year events and of the PP quar-
tile in categories, no evidence of linear trend was found.
The association of PP for different levels of SBP was also
explored and it was found that a BP between 100 and
139 mmHg conferred a 11.8% and 16.6% significant relative
risk reduction in all-cause deaths for every 10 mmHg increase
of PP in the unadjusted and adjusted models, respectively,
whereas no relationship with outcomes was found for SBP
below and above these thresholds (Table 3). The estimated
cumulative incidence of all-cause death according to PP quar-
tiles in HFrEF showed an increase of probability of a fatal
event with the decline in PP amplitude (P = 0.0006). In con-
trast, no prognostic measurable differences among PP quar-
tiles were observed in the HFmEF group. Similar neutral
results were seen by combining PP and SBP (Table 4). In
HFpEF, Cox proportional hazard models showed a 40.2%
and 44.3% significantly lower unadjusted and adjusted
Pulse pressure and heart failure 3
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relative risk of death respectively in the intermediate quartile
of PP compared to patients in the lowest quartile, in which
the probability of a fatal event is slightly more elevated.
(P = 0.031). This was confirmed also for the cumulative all-
cause deaths. As shown in the Table 4, we did not find any
relationship between PP and different levels of SBP in both
unadjusted and adjusted models. As shown in the Supporting
Information, Tables S2 and S3, the number of patients, partic-
ularly in the category of SBP < 100 mmHg in HFmEF and in
HFpEF, is relatively low that may have weaken the statistical
power of this SBP subgroup analysis.
Pulse pressure as marker of preserved vs.
reduced left ventricular ejection fraction
We conducted a ROC analyses to evaluate the potential role
of PP as marker of a preserved LVEF (≥ 50%), measured on
hospital admission, in individual AHF patients (Figure 1).
When only PP > 60 mmHg was considered and analysed as
a continuous variable, its ability in detecting an EF ≥ 50%
was low (the ROC area under curve was 66.6%). On the other
hand, when the highest quartile of PP > 60 mmHg was com-
bined with SBP > 140 mmHg, the ROC curve area coefficient
was 76.1% suggesting a remarkable sensitivity and specificity
of this combination to suggest a preserved LVEF in this clinical
context.
Discussion
The salient findings of our study, performed in patients with
acute HF, are the following: (i) in HFrEF, intermediate and
highest quartiles of PP showed a lower mortality as compared
to the lowest quartile with an almost inverse linear relation-
ship, at least in part mediated by SBP; (ii) in HFmEF, PP did
not show any relationship to prognosis; (iii) in HFpEF, inter-
mediate quartiles of PP showed a better prognostic value
suggesting a J-curve with a more favourable PP value at the
nadir of the curve, with no relationship with SBP; (iv) the
combination of PP > 60mmHg and SBP > 140mmHg was as-
sociated with a preserved LVEF suggesting a clinical relevance
of this combination in discriminating these HF phenotypes.
Longitudinal community studies like the Framingham Heart
study21 and the Multiethnic Study of Atherosclerosis22
showed that the brachial PP, in particular the pulse wave ve-
locity and the pulse reflection magnitude respectively, were
strong predictors for incident HF. Several studies on the prog-
nostic role of PP in established chronic HF were conducted
with non-consistent results.6,9–14,23–25 In acute HF, most of
the work focused on the prognostic impact of the SBP, a
meaningful indicator, and the potential prognostic role of
PP has been less explored.26–30
Our data in HFrEF are in line with the results of both Vaso-
dilation in the Management of Acute-HF study11 and (Meta-
Analysis Global Group in Chronic Heart Failure) MAGGIC
meta-analysis12 on the prognostic value of PP in acute HFrEF
(with a cut-off value of EF < 40% and < 50% respectively)
that found that the patients in the lowest PP had the worst
prognosis with an association more pronounced if PP was
measured within 24 hours after admission11 (with EF).12 Sim-
ilarly to our results, the prognostic role of PP was interpreted
according to corresponding SBP values.12 Higher PP was asso-
ciated to higher SBP and higher LVEF suggesting that stroke
volume and SBP are probably the major determinants of its
amplitude in this setting.11,12
Differently from our data, the Get With The Guidelines
(GWTG) Registry13 reported a U-shaped association between
PP at discharge and mortality in patients with HFrEF (EF cut-
off at 50%) with a risk nadir at PP of 50mmHg. Risk decreased
as PP increased up to 50 mmHg, whereas risk increased as PP
increased ≥50 mmHg suggesting that for lower PP the LV
function is the main determinant of its amplitude, whereas
for higher PP arterial stiffness plays a major role. In our pop-
ulation, although intermediate quartiles of PP showed the
best prognosis, this significant positive trend was maintained
also for higher PP quartiles suggesting an almost linear rela-
tion between PP amplitude and reduced mortality further
supporting the predominant role of LV pump in determining
the PP amplitude in HFrEF. No data were reported in the
above studies about the role of PP in the “grey” zone of
HFmEF patients. We did not observe any relationship be-
tween PP and mortality in this intermediate cohort, and even
by comparing the EF subgroups obtained by a single cut-off
value of 50%, the results of PP interaction in HFrEF and HFpEF
did not change substantially (data not shown). The lack of
Table 2 Outcomes at 1 year according to the left ventricular ejection fraction phenotypes
Phenotypes n HFrEF 2213 HFmEF 818 HFpEF 1283 P value
1 year all cause death 534/1944 (27.5%) 141/730 (19.3%) 244/1151 (21.2%) < 0.001
1 year cardiovascular death 270/1731 (15.6%) 68/682 (10.0%) 113/1071 (10.6%) < 0.001
Cumulative (in-hospital + 1 year) all cause death 643/2053 (31.3%) 180/769 (23.4%) 313/1220 (25.7%) < 0.001
In-hospital death 109/2212 (4.9%) 39/818 (4.8%) 69/1283 (5.4%) 0.782
1 year all cause rehospitalization (at least 1) 887/1777 (49.9%) 288/694 (41.5%) 524/1081 (48.5%) < 0.001
1 year cardiovascular rehospitalization (at least 1) 754/1744 (43.2%) 239/687 (34.8%) 386/1066 (36.2%) < 0.001
HFmEF, heart failure with mid-range ejection fraction; HFpEF, heart failure with preserved ejection fraction; HFrEF, heart failure with re-
duced ejection fraction.
Pulse pressure and heart failure 5
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relation between PP and any of the prognostic outcomes con-
sidered in the intermediate EF group remains unexplained,
but it could be related to the very narrow range of EF and a
too low number of patients and events.
In acute HFpEF, the prognostic impact of PP is more com-
plex. In our study and in another recent report,14 the inter-
mediate quartiles of PP showed a better prognosis
compared to the lowest and the highest quartiles with no re-
lationship with the level of SBP. This suggests that in HFpEF
attributing the relative weight of PP amplitude to arterial
stiffness or to LV systolic function may be harder than in
HFrEF, and probably, the better prognostic impact of inter-
mediate values of PP is associated with a more favourable
ventricular–vascular coupling compared to higher or lower
values of PP. Differently from our results, in the GWTG Regis-
try,13 the patients with HFpEF showed increasing risk of mor-
tality as PP increases, and this was mediated by increasing
SBP suggesting a predominant role of arterial stiffening over
LV systolic function. On the contrary, in the acute HFpEF pa-
tients of the MAGGIC meta-analysis,12 those in the lowest
quintile of PP had the worst outcome irrespective of the level
of SBP, suggesting a prevalent role of a transient alteration in
LV systolic performance during the acute episode.
The relative contribution of the single determinants of PP
amplitude is dynamic and varies in relation to the clinical sit-
uation and the precise timing at which the measurement is
performed. In fact, changes over time of its amplitude during
hospital stay have been described.30 Of course PP measured
on admission is not the same as PP taken days after or at dis-
charge from the initial acute episode, and PP taken early on
admission showed the worst prognostic impact.11 Our deter-
minations of PP are on hospital admission whereas in the
GWTG Registry13 were taken at hospital discharge, and in
both the MAGGIC meta-analysis12 and the Tokitsu study,14
data of PP were measured at variable time during hospital
stay. This might help to explain the apparent discrepancy ob-
served in the literature regarding its prognostic behaviour
The fact that a lower PP is associated with a worse progno-
sis does not exclude a major role also of arterial stiffening in
determining its narrowing rather than its widening. In fact
under stress conditions such as during physical exercise, HFrEF
patients with stiffer arteries had lower PP amplitude com-
pared to those with more distensible elastic arteries.7 Simi-
larly, in HFpEF, an altered ventricular–vascular coupling
reserve may determine a lesser increase in LVEF and in PP am-
plitude compared to normal subjects.31 This increased burden
on the left ventricle related to a stiffer vascular system ob-
served during exercise in both HFrEF, and HFpEF may resem-
ble what happens during an acute episode of HF leading to a
narrower PP. This may also explain the opposite negative
prognostic behaviour of low PP and high pulse wave velocity,
a direct measure of arterial stiffness, observed in patients with
chronic HFrEF.32 In a recent study comparing 22 hypertensive
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exercise testing with invasively measured radial artery pres-
sure waveform, the HFpEF subjects displayed reduced total
arterial compliance and higher effective arterial elastance at
similar mean arterial pressures in control subjects. This was di-
rectly correlated with higher ventricular filling pressures and
depressed cardiac output reserve.33
Also, the presence of atrial fibrillation may at least in part
contribute to a narrower PP in acute HF probably because
of a reduction in atrial contribution to LV filling with a conse-
quent further reduction in stroke volume. This may reconcile
the apparent discrepancy with earlier studies showing that
higher PP is a predictor of incident AF whereas in our study
as well as in the MAGGIC meta-analyses12 a lower PP relates
to higher prevalence of AF.
Finally, the results of our study also suggest a potential
clinical role of PP. Acute HFrEF and HFpEF present with similar
clinical symptoms and signs, and only imaging techniques can
really differentiate the LVEF phenotipes.15 In previous stud-
ies, a low proportional PP index (PP/SBP) has shown to corre-
late with LV systolic performance in HFrEF.34 In our study, a
combination with PP > 60 mmHg and a SBP > 140 mmHg
has been shown to discriminate a preserved EF providing a
support for a phenotypic diagnosis and some insight in the
pathogenetic pattern of these two clinical entities.
Table 4 Hazard ratios for association of pulse pressure with 1 year all-cause death in A HFrEF ( n 2213), B HFmEF ( n 818) and C HFpEF (n
1283) for different level of SBP (Cox proportional hazard models)
Variable SBP level, mmHg Unadjusted HR (95% CI) P value Adjusted HRa (95% CI) P value
A
1 year all-cause death SBP < 100 0.95 (0.71–1.27) 0.748 0.83 (0.618–1.13) 0.241
100 ≤ SBP < 140 0.88 (0.79–0.98) 0.023 0.83 (0.748–0.93) 0.001
SBP ≥ 140 1.12 (1.00–1.25) 0.046 1.08 (0.961–1.21) 0.201
B
1 year all-cause death SBP < 100 1.09 (0.54–2.22) 0.803 1.28 (0.64–2.53) 0.484
100 ≤ SBP < 140 1.15 (0.92–1.43) 0.230 1.16 (0.92–1.46) 0.202
SBP ≥ 140 1.10 (0.94–1.28) 0.229 0.97 (0.83–1.14) 0.711
C
1 year all-cause death SBP < 100 0.87 (0.47–1.63) 0.663 0.72 (0.36–1.41) 0.335
100 ≤ SBP < 140 1.05 (0.90–1.21) 0.552 0.94 (0.81–1.09) 0.441
SBP ≥ 140 1.09 (0.98–1.20) 0.105 1.04 (0.94–1.15) 0.469
CI, confidence interval; HFmEF, heart failure with mid-range ejection fraction; HFpEF, heart failure with preserved ejection fraction; HFrEF,
heart failure with reduced ejection fraction; HR, hazard ratio; SBP, systolic blood pressure.
Fisher’s test.
HRs Adjusted per every 10 mmHg increase of PP.
aCovariates: age, gender, heart failure aetiology (ischemic/non-ischemic), diabetes, renal function
Figure 1 Receiving operator characteristics (ROC) curve of PP > 60 mmHgcombined with SBP > 140 mmHg in predicting a preserved ejection fraction
(>50%) in AHF (ROC curve area 0.761).
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Study limitations
Several issues regarding our study must be acknowledged.
First, by considering the presumable high proportion of pa-
tients needing immediate treatment at enrollment (in fact
88% were in NYHA functional class III–IV), and to foster the
consecutiveness of enrollment, specific modalities of BP mea-
surements were not mandated by protocol. This may expose
to some imprecision in the BP-reported values. However, the
reported level of BP was that used by the attending physi-
cians to take the clinical decisions for patients’ management.
Second, the observational, pragmatic methodology of our
large study does not allow a definite proof of a direct link be-
tween PP amplitude and outcome. Third, a recent compre-
hensive technical, physiopathological, and clinical review on
pulsatile hemodynamics in various HF conditions also outlines
the limitation of inferring the PP between two points mea-
sured at the clinical bed.29 However, some information can
be drawn by this simple measurement, and we tried to ex-
plore this area of clinical knowledge. Fourth, we have only
one time-point measurement, and we cannot evaluate the
potential—likely relevant—prognostic role of changes over
time of PP, and we cannot exclude unmet or unknown con-
founding factors that may have influenced its prognostic im-
pact. Fifth, we do not have information about central PP,
found to be a stronger prognostic marker than brachial PP
in various conditions.21,35 Sixth, we also lack of direct mea-
surements of arterial stiffness like the aortic pulse wave ve-
locity that showed prognostic impact in chronic HFrEF32,36
and HFpEF.14 However, though warranted, central PP and
aortic pulse wave velocity have never been measured in any
large trial in acute HF and cannot be implemented in a large
multinational setting of non-tertiary cardiology centres like
the present registry.
Conclusions
Brachial PP has a prognostic value and a potential contribu-
tory diagnostic role in acute HF. In HFrEF, an almost linear, in-
verse relationship between mortality and PP, partly mediated
by SBP, was shown. In HFpEF, a J-shaped relationship be-
tween mortality and PP was observed with no evident rela-
tionship to the level of SBP. A combination of PP and SBP
may result as clinically helpful to discriminate the two differ-
ent major phenotypes of HF.
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